BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11754353)

  • 1. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
    Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
    Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.
    Hosch SB; Scheunemann P; Lüth M; Inndorf S; Stoecklein NH; Erbersdobler A; Rehders A; Gundlach M; Knoefel WT; Izbicki JR
    J Gastrointest Surg; 2001; 5(6):673-9. PubMed ID: 12086907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.
    Gelderman KA; Hakulinen J; Hagenaars M; Kuppen PJ; Meri S; Gorter A
    Mol Immunol; 2003 Sep; 40(1):13-23. PubMed ID: 12909127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
    Iborra A; Mayorga M; Llobet N; Martínez P
    Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
    Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
    J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
    Gelderman KA; Lam S; Sier CF; Gorter A
    Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human nasal epithelium adsorbs complement C3-related fragments and expresses cell membrane complement regulatory proteins.
    Varsano S; Frolkis I; Shapiro H; Ophir D
    Laryngoscope; 1996 May; 106(5 Pt 1):599-604. PubMed ID: 8628088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model.
    Gelderman KA; Kuppen PJ; Okada N; Fleuren GJ; Gorter A
    Cancer Res; 2004 Jun; 64(12):4366-72. PubMed ID: 15205353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
    Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
    Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
    Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
    Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-regulatory proteins in ovarian malignancies.
    Bjørge L; Hakulinen J; Wahlström T; Matre R; Meri S
    Int J Cancer; 1997 Jan; 70(1):14-25. PubMed ID: 8985085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
    Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
    Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.